Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol (“CBD”) therapy. The study is evaluating Lexaria’s patented DehydraTECH(TM)-CBD capsule formulation. LEXX reported that study results showed exceptional safety and tolerability and statistically significant lowering of 24-hour ambulatory BP as well as BP lowered for the duration of the entire five-week study. The study also indicated lowered BP for patients currently taking other antihypertensive drugs as well as patients not taking any other antihypertensive drugs. According to the announcement, Lexaria is aware of only a few other published stories designed to evaluate whether a sustained decrease in resting BP is possible following multiple weeks of oral CBD dosing, with none of those studies showing successful results. “That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” said Lexaria Bioscience Corp. CEO Chris Bunka in the press release. “DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study. Indeed, of the handful of minor, nonserious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD. Consistent with Lexaria’s often-mentioned, de-risking strategy, this exceptional safety profile should prove beneficial as we prepare for our planned upcoming phase Ib Investigational New Drug clinical study to be registered with the U.S. Food and Drug Administration.”
To view the full press release, visit https://ibn.fm/uEM2e
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.